India

Panacea Biotec Limited

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine

Lead Product(s): Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Refana

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 10, 2020

Details:

Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World.

LAXAI Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: LAXAI Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2020

Details:

Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform SCULPT™, which are currently being synthesized and will be evaluated by Laxai.

Sun Pharmaceutical Industries Limited

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sun Pharma to Trial Nafamostat for Covid-19 Treatment

Lead Product(s): Nafamostat

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea.

Brinton Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Brinton Pharmato Launch Favipiravir, a Promising Drug for COVID-19

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Favipiravir will be marketed by Brinton Pharmaceuticals under the brand name Faviton. Faviton will be initially launched in 18 countries where Brinton has its own presence. In India, It will be launched once DCGI approval process is completed.

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Glenmark to conduct trials in India for potential COVID-19 drug

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

The trials come after a Chinese official told reporters last month that an active ingredient of the drug had been effective, with no obvious side effects, in helping coronavirus patients recover.

Premas Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach

Lead Product(s): Recombinant triple antigen vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

Premas Biotech has adopted a three-pronged approach to develop multi subunit vaccine, using recombinantly expressed antigens Spike, Envelope, and Membrane proteins in multiple formats.

Cadila Healthcare Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine

Lead Product(s): DNA Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: The Department of Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding April 20, 2020

Details:

Funding to support Cadila Healthcare for advancing its DNA Vaccine candidate against SARS-CoV-2 and to Bharat Biotech for COVID-19 vaccine candidate utilising the inactivated rabies vector platform.

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b

Lead Product(s): Interferon alpha-2b

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2020

Details:

Interferon alpha can potentially emerge as one of the treatment options for COVID 19; In vitro and in vivo studies suggest positive effects on COVID-19 Patients.

Seagull Biosolutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine

Lead Product(s): Active virosome vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: The Union science and technology ministry of India

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding April 12, 2020

Details:

The Union science and technology ministry will fund Seagull Biosolutions to develop a vaccine for Covid-19 which is expected to enter phase-1 trial in 18-20 months.

Vopec Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 26, 2020

Details:

Vopec Pharmaceuticals has received the NOC and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Panacea Biotec Limited

Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine

LAXAI Life Sciences

A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

Sun Pharmaceutical Industries Limited

Sun Pharma to Trial Nafamostat for Covid-19 Treatment

Brinton Pharmaceuticals

Brinton Pharmato Launch Favipiravir, a Promising Drug for COVID-19

Glenmark

Glenmark to conduct trials in India for potential COVID-19 drug

Premas Biotech

Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach

Cadila Healthcare Ltd

Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine

Zydus Cadila

Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b

Seagull Biosolutions

Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine

Vopec Pharmaceuticals

Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19